Bright Minds Biosciences Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Bright Minds Biosciences is in Stage 4, the downtrend phase, now in week 5 (since Sep 23, 2026). It closed at $52.69, 45.1% below its 52-week high and below its 200-day average, which is falling.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. More about the company

$52.69

+4.46% today

$520M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is DRUG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 18w

S2 14w

S3 20w

S2 27w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 2w → S4 19w → S1 10w → S4 18w → S1 3w → S4 4w → S1 5w → S2 14w → S3 20w → S4 8w → S1 4w → S2 27w → S3 6w → S2 8w → S3 3w → S4 6w → S1 4w → S4 4w current

Total tracked: 164 weeks across 18 stage runs.

DRUG among Biotechnology262nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…262	DRUGBright Minds Biosciences Inc.	Stage 4 · wk 5	37	−9.0%

vs 52W High

-45.1%

$48.25 lo$95.99 hi

45.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-29.1%

200 DMA: $74.35 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.79x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-9.0%

-26.1%

-40.6%

YTD

-36.9%

-24.1%

Scan Membership

Breakout Watch

Latest: 2024-10-15

2 appearances in last 60 days. First seen: 2022-10-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 1.79x

2026-10-21S4

Wk 5 · Vol 1.11x

2026-10-20S4

Wk 4 · Vol 0.74x

2026-10-19S4

Wk 4 · Vol 1.22x

2026-10-16S4

Wk 4 · Vol 0.43x

2026-10-15S4

Wk 4 · Vol 0.94x

2026-10-14S4

Wk 4 · Vol 1.54x

2026-10-13S4

Wk 3 · Vol 1.90x

2026-10-12S4

Wk 3 · Vol 1.02x

2026-10-09S4

Wk 3 · Vol 0.74x

2026-10-08S4

Wk 3 · Vol 0.50x

2026-10-07S4

Wk 3 · Vol 5.42x

Moving averages & range

50 DMA

$62.31

200 DMA

$74.35

52W High

$95.99

52W Low

$48.25

5D Low

$50.44

Resistance levels (recent highs)

20d High

$55.20

60d High

$84.74

120d High

$89.49

250d High

$95.99

Next resistance

+4.8%

to 20d High

ROE

-13.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.4

Bright Minds Biosciences: quick answers

What stage is Bright Minds Biosciences in?

As of Oct 22, 2026, Bright Minds Biosciences (DRUG) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 23, 2026 and is in week 5. What the four stages mean

Is Bright Minds Biosciences in an uptrend?

No. Bright Minds Biosciences is in a Stage 4 downtrend. It trades 29.1% below its 200-day average, which is falling.

How far is Bright Minds Biosciences from its 52-week high?

Bright Minds Biosciences closed at $52.69 on Oct 22, 2026, 45.1% below its 52-week high of $95.99. Its 52-week low is $48.25.

How has Bright Minds Biosciences performed over the past year?

As of Oct 22, 2026, Bright Minds Biosciences is down 24.1% over the past year and down 36.9% so far in 2026.

Which sector and industry is Bright Minds Biosciences in?

Bright Minds Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.